Wilsons Disease Treatment Market - Size, Share, Growth, Outlook, and Opportunity Analysis, 2018-2026 Wilson’s disease, also known as hepatolenticular degeneration or progressive lenticular degeneration, is a rare genetic disorder caused by copper poisoning in the body. In a healthy body, the liver filters the excess copper and releases it through urine. The liver of a person suffering from Wilson’s disease cannot perform this function. Wilson’s disease is diagnosed by blood tests where abnormalities in liver enzymes, copper levels in the blood, lower levels of ceruloplasmin, a protein that carries copper through the blood, a mutated gene or low blood sugar. Treatment include oral drug containing zinc, d-penicillamine, Tetrathiomolybdate and trientine or syprine.
Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/526
Increasing awareness regarding Wilson’s disease and its symptoms is expected to fuel the market of Wilson’s disease treatment market in the near future. Moreover, growing population all over the world is expected to boost the growth of Wilson’s disease market.
Market Dynamics Rising incidence of Wilson’s disease is due to increase in the population worldwide as Wilson’s disease is a rare genetic disorder which, is expected to favor the demand for Wilson’s disease treatment market around the globe. According to the European Association for the study of liver (EASL) in 2011 published that Wilson’s disease is a genetic disorder that is found worldwide and is recognized to be more common than previous, with a gene frequency of 1 in 90 -150 and an incidence that is 1 in 30,000 and more than 500 distinct mutations are described in the Wilson’s gene from which 380 have a confirmed role in the pathogenesis of the disease. Whereas, European Association also stated in year 2011 that Wilson’s disease accounts for 6 - 12% of all patient with acute liver failure who are referred for emergency transplantation.